Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 6,918 shares of the company's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $35.52, for a total transaction of $245,727.36. Following the transaction, the chief executive officer directly owned 526,034 shares of the company's stock, valued at approximately $18,684,727.68. This trade represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Ying Du also recently made the following trade(s):

• On Thursday, June 26th, Ying Du sold 23,669 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total value of $855,160.97.
• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $28.57, for a total value of $1,428,500.00.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The shares were sold at an average price of $28.09, for a total transaction of $1,303,067.01.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The stock was sold at an average price of $33.11, for a total transaction of $97,508.95.
• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total value of $208,449.12.

Zai Lab Trading Up 0.6%

NASDAQ:ZLAB traded up $0.20 during trading hours on Tuesday, reaching $35.17. 412,361 shares of the company traded hands, compared to its average volume of 907,152. Zai Lab Limited Unsponsored ADR has a 1 year low of $16.01 and a 1 year high of $44.34. The stock has a market capitalization of $3.91 billion, a P/E ratio of -14.12 and a beta of 0.96. The business's 50-day moving average price is $33.57 and its two-hundred day moving average price is $31.19.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. The company had revenue of $106.49 million for the quarter, compared to analysts' expectations of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. As a group, equities analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ZLAB. GF Fund Management CO. LTD. purchased a new position in Zai Lab in the 4th quarter worth approximately $29,000. Pictet Asset Management Holding SA bought a new stake in shares of Zai Lab in the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Zai Lab in the first quarter worth $75,000. Barclays PLC lifted its holdings in shares of Zai Lab by 337.6% during the fourth quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after purchasing an additional 2,856 shares in the last quarter. Finally, Advisors Preferred LLC purchased a new stake in shares of Zai Lab during the first quarter valued at $110,000. Institutional investors own 41.65% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Wall Street Zen lowered Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday. Leerink Partners increased their price objective on Zai Lab from $73.00 to $75.00 and gave the stock an "outperform" rating in a report on Monday. Bank of America reissued a "neutral" rating and set a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a research report on Thursday, March 27th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research report on Thursday, March 13th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $54.28.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.